https://charts.traderzeitung.de/phases/US82657M1053 string(1395) "{"isin":"US82657M1053","name":"Sight Sciences Inc","stock_id_xnas":22560784,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.495,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.595,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":1.1772},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.5,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-1.1053},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Sight Sciences Aktie News & Nachrichten

[WKN: A3CU4L | Symbol: SGHT]

Realtimekurs

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Sight Sciences gefunden werden.

Sight Sciences Nachrichtenticker öffnen

MT Newswires 19.08.2026 21:51 Uhr

Sight Sciences Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Sektor-Update: Gesundheitsaktien legen am späten Nachmittag zu

Sektor-Update: Gesundheitsaktien legen am Mittwochnachmittag zu

Branchen-Update: Gesundheitsaktien im Mittwochshandel im Plus

Sight Sciences erhält US-FDA-Label-Erweiterung für TearCare-Behandlung des trockenen Auges

UBS passt Kursziel für Sight Sciences von 7 auf 8 US-Dollar an, hält an Kaufempfehlung fest

UBS senkt Kursziel für Sight Sciences von 11 $ auf 7 $, beibehält Kaufempfehlung